CMP: 1460

Abbott India Limited manufactures a wide range of pharmaceutical and medical products, agrochemicals, and animal health products. The Company's medical and pharmaceutical products include insulin injections, anti-dysentery drugs, vitamin preparations, penicillin preparations, sulfonamide tablets, and a variety of household remedies.

Abbott India is a decent bet in mid-cap pharma space. Its currently trading at a P/E of 34 with dividend yields above 1% in the last 12 months. It runs at zero debt with 72 Crores cash in hand. Revenues have grown steadily from 594 Crores to 1019 Crores in the last 5 years. Profits have been pretty much static above 60 Crores in the last 5 years with dropping NPM. NPM has dropped from over 10% to 6% over 5 years. 2012 quarters have show much better promise in-terms of growth with projected earnings at 100 Crores. Buy and hold for long term gains.